FDA rejects Hengrui and Elevar Therapeutics' liver cancer combo for a third time, citing new manufacturing issues.
For the third time in about two years, the FDA has cited manufacturing deficiencies in rejecting a drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time
HLB liver cancer drug hits FDA setback again over manufacturing issues
HLB resolves issues behind FDA setback for novel liver cancer drug - The Korea Times
FDA hurdle cleared for liver cancer drug application: HLB
段永平增持泡泡玛特 持股比例升至7.65%-36氪
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and…
Even though Hengrui Pharma has resolved the manufacturing problems cited in a recent FDA complete response letter, a second…
HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug…
The U.S. Food and Drug Administration (FDA) has determined that the inspection findings behind its rejection of HLB's liver…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery…
